Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LYRANASDAQ:PYPDNASDAQ:TELANASDAQ:TMDI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$6.22-4.7%$5.34$1.91▼$6.79$371.58M0.2312,374 shs1.15 million shsPYPDPolyPid$5.00+6.4%$5.85$3.57▼$14.70$24M1.437,489 shs4,573 shsTELATELA Bio$5.67+1.1%$6.57$4.23▼$11.65$139.77M0.97114,203 shs82,453 shsTMDITitan Medical$0.14-26.3%$0.23$0.13▼$1.20$15.67M2.364.83 million shs7.71 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics-4.75%+2.47%+14.97%+18.70%+206.40%PYPDPolyPid+6.38%-3.66%-8.59%+31.58%-57.81%TELATELA Bio+1.07%+5.98%-19.12%-14.35%-48.59%TMDITitan Medical0.00%0.00%0.00%0.00%0.00%[BUY ALERT] Our #1 A.I. Stock for March (Ad)It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLYRALyra Therapeutics2.4382 of 5 stars3.53.00.00.03.12.50.0PYPDPolyPidN/AN/AN/AN/AN/AN/AN/AN/ATELATELA Bio2.1869 of 5 stars3.52.00.00.03.01.70.6TMDITitan MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLYRALyra Therapeutics3.00Buy$12.67103.64% UpsidePYPDPolyPid3.00BuyN/AN/ATELATELA Bio3.00Buy$13.67141.03% UpsideTMDITitan MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest PYPD, TMDI, TELA, and LYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024LYRALyra TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/22/2024LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/22/2024TELATELA BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.003/22/2024TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.001/12/2024LYRALyra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLYRALyra Therapeutics$1.56M238.19N/AN/A$2.54 per share2.45PYPDPolyPidN/AN/AN/AN/A($1.27) per shareN/ATELATELA Bio$58.45M2.39N/AN/A$0.75 per share7.56TMDITitan Medical$20.09M0.78N/AN/A$0.32 per share0.44Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLYRALyra Therapeutics-$62.68M-$1.29N/AN/AN/A-4,023.11%-72.62%-50.90%5/10/2024 (Estimated)PYPDPolyPid-$23.86M-$19.68N/AN/AN/AN/A-450.37%-101.27%5/8/2024 (Estimated)TELATELA Bio-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Estimated)TMDITitan Medical-$14.86M-$0.19N/A∞N/AN/A-167.03%-112.15%N/ALatest PYPD, TMDI, TELA, and LYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2024Q4 2023PYPDPolyPid-$2.17-$3.97-$1.80-$3.97N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLYRALyra TherapeuticsN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLYRALyra TherapeuticsN/A5.355.45PYPDPolyPid2.170.830.83TELATELA Bio2.154.234.43TMDITitan MedicalN/A1.411.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLYRALyra Therapeutics95.62%PYPDPolyPid26.47%TELATELA Bio94.35%TMDITitan Medical3.55%Insider OwnershipCompanyInsider OwnershipLYRALyra Therapeutics17.42%PYPDPolyPid24.70%TELATELA Bio5.70%TMDITitan Medical0.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLYRALyra Therapeutics7859.74 million49.34 millionOptionablePYPDPolyPid574.80 million3.61 millionOptionableTELATELA Bio17324.65 million23.25 millionOptionableTMDITitan Medical49111.95 million111.93 millionNot OptionablePYPD, TMDI, TELA, and LYRA HeadlinesSourceHeadlineTitan Medical signs deal to merge with Conavi Medicalmsn.com - March 21 at 4:35 AMTitan Medical Inc TMDIFmorningstar.com - February 27 at 7:19 PMPerifery appoints Titan Data Solutions as authorised distributoradvanced-television.com - February 13 at 8:31 AMTitan Medical Inc (TMD)investing.com - February 13 at 1:56 AMVantage Titan 3T MRI Scanner from Toshibanews-medical.net - January 11 at 8:10 AMAttack on Titan: Hajime Isayama Will Create New Titan Story in 2024comicbook.com - October 3 at 1:41 AMFive dead on Titan sub were 'true explorers' - OceanGatebbc.com - September 28 at 10:21 PMTMDIF Titan Medical Inc.seekingalpha.com - August 1 at 7:27 PMFalse claim Titan passenger was the vice chairman of the World Economic Forum | Fact checkusatoday.com - July 25 at 1:09 PMNew details emerge about discovery of Titan submersible debrisen.as.com - July 19 at 9:22 AMDestiny 2 best Titan build for PvE and PvPvideogamer.com - July 18 at 7:32 AMPresumed human remains found in Titan sub debrisbbc.co.uk - July 14 at 5:59 PMThe Titan submersible imploded, killing all 5 on boardasahi.com - July 9 at 10:09 AMDebris and 'Presumed Human Remains' Recovered From Titan Submersiblemsn.com - June 30 at 7:39 PMUS Coast Guard says 'presumed human remains' found in wreckage of Titan submersiblewbaltv.com - June 30 at 1:27 PMTitan Sub Tragedy: "Presumed Human Remains" and Mangled Debris Recovered From Atlantic Oceaneonline.com - June 29 at 9:37 AMPossible human remains recovered from Titan wreckage, Coast Guard saysmsn.com - June 28 at 11:36 PMTitan submersible tragedy could lead to lawsuits and regulatory changes, experts sayyahoo.com - June 24 at 12:27 PMWhat happens during a catastrophic implosion? Titan submersible occupants likely died instantlywinknews.com - June 24 at 1:01 AMThe science that put the Titan submersible at risk of implosionktbs.com - June 24 at 1:01 AMThe Titan submersible: What could have gone wrong?msn.com - June 21 at 2:23 PMReport: Banging sounds heard during Titan submersible search, according to internal memowlox.com - June 21 at 12:43 AMTitan Medical Shares Slide as Company Pivots to IP Licensingmarketwatch.com - June 20 at 2:37 PMTitan Medical completes transition to becoming an IP licensing companycanadianmanufacturing.com - June 20 at 2:37 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksHims & Hers Stock Rises On Stimulating Earnings GrowthMarch 5, 2024 6:05 AMView Hims & Hers Stock Rises On Stimulating Earnings GrowthLifeMD Shares Come Back to Life on GLP-1 Business Growth March 19, 2024 6:05 AMView LifeMD Shares Come Back to Life on GLP-1 Business Growth All Headlines Company DescriptionsLyra TherapeuticsNASDAQ:LYRALyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.PolyPidNASDAQ:PYPDPolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.TELA BioNASDAQ:TELATELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Titan MedicalNASDAQ:TMDITitan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.